antibody-based regulation mechanism

Bonum Therapeutics uses a novel, antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Its therapeutics remain inactive until bound to their target, a reversible regulation mechanism. The company is developing antibody-controlled cytokine-based therapeutics designed to enhance the anti-tumor immune response, with two programs in preclinical development. Its pipeline is focused on cancer, with interest in autoimmune disease, metabolic disorders, and pain management.

Read more

preclinical developmentprotein therapeutic engineering